Last reviewed · How we verify
HYDRALAZINE
At a glance
| Generic name | HYDRALAZINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
- Headache
- Anorexia
- Nausea
- Vomiting
- Diarrhea
- Palpitations
- Tachycardia
- Angina pectoris
Serious adverse events
- Agranulocytosis
- Blood dyscrasias
- Leukopenia
- Hepatitis
- Psychotic reactions
- Paralytic ileus
- Peripheral neuritis
- Hypotension
- Dyspnea
- Paradoxical pressor response
Key clinical trials
- Baroreflex Activation Therapy for Heart Failure (NA)
- DANHEART (H-HeFT and Met-HeFT) (PHASE4)
- Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension (PHASE2)
- Comparison of Post-Craniotomy Blood Pressure Targets (NA)
- Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension (NA)
- Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer (PHASE3)
- Intravenous Labetalol Versus Hydralazine in Preeclampsia (PHASE1, PHASE2)
- The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HYDRALAZINE CI brief — competitive landscape report
- HYDRALAZINE updates RSS · CI watch RSS